196 related articles for article (PubMed ID: 29387745)
1. Intracranial regression of an advanced basal cell carcinoma using sonidegib and itraconazole after failure with vismodegib.
Yoon J; Apicelli AJ; Pavlopoulos TV
JAAD Case Rep; 2018 Jan; 4(1):10-12. PubMed ID: 29387745
[No Abstract] [Full Text] [Related]
2. Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas.
Wahid M; Jawed A; Mandal RK; Dar SA; Khan S; Akhter N; Haque S
Crit Rev Oncol Hematol; 2016 Feb; 98():235-41. PubMed ID: 26614022
[TBL] [Abstract][Full Text] [Related]
3. Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas.
Jain S; Song R; Xie J
Onco Targets Ther; 2017; 10():1645-1653. PubMed ID: 28352196
[TBL] [Abstract][Full Text] [Related]
4. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.
Danial C; Sarin KY; Oro AE; Chang AL
Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616
[TBL] [Abstract][Full Text] [Related]
5. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
Li Y; Song Q; Day BW
Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
[TBL] [Abstract][Full Text] [Related]
6. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
Dummer R; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Gogov S; Pallaud C; Yi T; Mone M; Chang AL; Cornélis F; Kudchadkar R; Trefzer U; Lear JT; Sellami D; Migden MR
J Am Acad Dermatol; 2016 Jul; 75(1):113-125.e5. PubMed ID: 27067394
[TBL] [Abstract][Full Text] [Related]
7. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.
Leavitt E; Lask G; Martin S
Curr Treat Options Oncol; 2019 Nov; 20(11):84. PubMed ID: 31773379
[TBL] [Abstract][Full Text] [Related]
8. Sonidegib phosphate: new approval for basal cell carcinoma.
Tibes R
Drugs Today (Barc); 2016 May; 52(5):295-303. PubMed ID: 27376162
[TBL] [Abstract][Full Text] [Related]
9. Sonidegib for the treatment of advanced basal cell carcinoma.
Ramelyte E; Amann VC; Dummer R
Expert Opin Pharmacother; 2016 Oct; 17(14):1963-8. PubMed ID: 27538055
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological evaluation of a series of smoothened antagonists in signaling pathways and after topical application in a depilated mouse model.
Lauressergues E; Heusler P; Lestienne F; Troulier D; Rauly-Lestienne I; Tourette A; Ailhaud MC; Cathala C; Tardif S; Denais-Laliève D; Calmettes MT; Degryse AD; Dumoulin A; De Vries L; Cussac D
Pharmacol Res Perspect; 2016 Apr; 4(2):e00214. PubMed ID: 27069629
[TBL] [Abstract][Full Text] [Related]
11. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
12. Sonidegib for the Treatment of Advanced Basal Cell Carcinoma.
Brancaccio G; Pea F; Moscarella E; Argenziano G
Front Oncol; 2020; 10():582866. PubMed ID: 33194718
[TBL] [Abstract][Full Text] [Related]
13. NL-103, a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations.
Zhao J; Quan H; Xie C; Lou L
Pharmacol Res Perspect; 2014 Jun; 2(3):e00043. PubMed ID: 25505589
[TBL] [Abstract][Full Text] [Related]
14. Hedgehog Pathway Inhibition.
Sekulic A; Von Hoff D
Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
[TBL] [Abstract][Full Text] [Related]
15. Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma.
Gutzmer R; Solomon JA
Target Oncol; 2019 Jun; 14(3):253-267. PubMed ID: 31243642
[TBL] [Abstract][Full Text] [Related]
16. Basal Cell Carcinoma and Hedgehog Pathway Inhibitors: Focus on Immune Response.
Gambini D; Passoni E; Nazzaro G; Beltramini G; Tomasello G; Ghidini M; Kuhn E; Garrone O
Front Med (Lausanne); 2022; 9():893063. PubMed ID: 35775005
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Hedgehog Pathway Inhibition on Nevoid Basal Cell Carcinoma Syndrome Fibroblasts and Basal Cell Carcinoma-Associated Fibroblasts: Are Vismodegib and Sonidegib Useful to Target Cancer-Prone Fibroblasts?
Eibenschutz L; Caputo S; Camera E; Carbone A; Silipo V; Migliano E; Aurizi C; Cota C; Frascione P; Bellei B
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34831015
[TBL] [Abstract][Full Text] [Related]
18. The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma.
Collier NJ; Ali FR; Lear JT
Expert Rev Anticancer Ther; 2016 Oct; 16(10):1011-8. PubMed ID: 27636236
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Hedgehog Pathway for Locally Advanced and Metastatic Basal Cell Carcinoma.
Yin VT; Esmaeli B
Curr Pharm Des; 2017; 23(4):655-659. PubMed ID: 27928965
[TBL] [Abstract][Full Text] [Related]
20. Strategies to target the Hedgehog signaling pathway for cancer therapy.
Xin M; Ji X; De La Cruz LK; Thareja S; Wang B
Med Res Rev; 2018 May; 38(3):870-913. PubMed ID: 29315702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
